Mangoceuticals Seeks Up to $10M in Tokenized 8% Preferred Stock Sale
MGRX sits 28% above its 52-week low of $0.162 on light trading volume (0.3× avg).
Summary
Mangoceuticals filed a Form 1-A offering statement to sell up to 1.0M shares of a new 8% Series D convertible preferred at $10.00 each, targeting up to $10M gross, with SEC qualification still pending. No common stock is issued at closing and conversion can't begin for three years, so near-term dilution is deferred. The raise is large relative to a company with a roughly $4.4M market cap and $229K of cash at the last 10-Q, which carried a going concern warning and Nasdaq bid-price risk. This follows the Nov 6 8-K in which the sole Series B holder approved the Series D, and the Nov 6 proxy seeking a 1-for-2 up to 1-for-25 reverse split to cure the bid-price deficiency. The company bills it as the first Nasdaq-listed tokenized preferred stock offering, on the t7x platform. Watch SEC qualification of the offering statement and the shareholder vote on the reverse split.
At the time of this announcement, MGRX was trading at $0.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $0.16 to $2.28. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.